22 active not recruiting. 22 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 22 | Active not recruiting 22 |
| Phase 1 | 5 | Active not recruiting 5 |
Follow Malignant Solid Neoplasm: new trials by email Literature Review of Malignant Solid Neoplasm trials Research Report on Malignant Solid Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial Binimetinib, Biopsy Procedure, Biospecimen Collection - Exocrine Pancreas Carcinoma, Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 199 | 2023-12-13 | 2026-08-21 |
| Evaluation of Broccoli Seed and Sprout Extract for Detoxification of Carcinogens in Firefighters Acetaminophen, Biospecimen Collection, Broccoli Sprout/Broccoli Seed Extract Supplement - Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 72 | 2023-12-04 | 2026-09-23 |
| Time-Restricted Eating Versus Nutritional Counseling for the Reduction of Radiation or Chemoradiation Tx Side Effects in Patients With Prostate, Cervical, or Rectal Cancers Biospecimen Collection, Informational Intervention, Quality-of-Life Assessment - Localized Prostate Carcinoma, Locally Advanced Cervical Carcinoma | Phase 2 | Active not recruiting | City of Hope Medical Center | 49 | 2023-03-23 | 2026-10-20 |
| Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors Atezolizumab, Biospecimen Collection, Computed Tomography - Atypical Teratoid/Rhabdoid Tumor, Epithelioid Sarcoma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 86 | 2022-11-17 | 2026-07-14 |
| Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial Biopsy Procedure, Biospecimen Collection, Computed Tomography - Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 14 | 2022-07-11 | 2026-10-14 |
| PEA for the Relief of Chemotherapy-Induced Peripheral Neuropathy Palmidrol, Placebo Administration, Quality-of-Life Assessment - Chemotherapy-Induced Peripheral Neuropathy, Hematopoietic and Lymphoid Cell Neoplasm | Phase 2 | Active not recruiting | Academic and Community Cancer Research United | 88 | 2022-05-16 | 2025-09-22 |
| Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma Ipilimumab, Nivolumab, Tocilizumab - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 35 | 2021-09-23 | 2026-09-16 |
| Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial Tipifarnib - Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 5 | 2020-10-13 | 2026-10-16 |
| Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia Best Practice, Mesenchymal Stem Cell - COVID-19 Infection, COVID-19-Associated Acute Respiratory Distress Syndrome | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 65 | 2020-07-29 | 2026-10-05 |
| Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy Duloxetine, Neurofeedback, Quality-of-Life Assessment - Chemotherapy-Induced Peripheral Neuropathy, Hematopoietic and Lymphoid Cell Neoplasm | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 336 | 2020-07-10 | 2026-06-24 |
| Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma Infliximab, Vedolizumab - Colitis, Lung Non-Small Cell Carcinoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 47 | 2020-07-09 | 2026-07-15 |
| Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - Malignant Solid Neoplasm, Refractory Cholangiocarcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 24 | 2020-01-30 | 2026-08-03 |
| Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G) Biopsy Procedure, Biospecimen Collection, Copanlisib - Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 22 | 2018-10-08 | 2026-10-19 |
| Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Mutations or Fusions (MATCH - Subprotocol K2) Biopsy Procedure, Biospecimen Collection, Computed Tomography - Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 35 | 2018-07-03 | 2026-10-15 |
| LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas Aldesleukin, Autologous Tumor Infiltrating Lymphocytes LN-145, Autologous Tumor Infiltrating Lymphocytes LN-145-S1 - Bone Sarcoma, Dedifferentiated Chondrosarcoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 30 | 2018-04-27 | 2026-05-22 |
| Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan - Advanced Malignant Solid Neoplasm, Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 13 | 2018-04-17 | 2026-10-28 |
| Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies Avelumab, Ivuxolimab, Radiation Therapy - Advanced Malignant Solid Neoplasm, Castration-Resistant Prostate Carcinoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 173 | 2017-08-02 | 2026-10-23 |
| Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J) Biopsy Procedure, Biospecimen Collection, Echocardiography Test - Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 35 | 2017-03-23 | 2026-07-30 |
| Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Biospecimen Collection, Computed Tomography, Echocardiography Test - Acinar Cell Carcinoma, Adenoid Cystic Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 798 | 2017-01-30 | 2026-06-17 |
| Donor Cytomegalovirus-Specific Cytotoxic T-Lymphocytes in Treating Patients With a Persistent Cytomegalovirus Infection Allogeneic Cytomegalovirus-Specific Cytotoxic T lymphocytes - Cytomegaloviral Infection, Hematopoietic and Lymphoid Cell Neoplasm | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 49 | 2015-02-19 | 2026-08-18 |
Showing 20 of 22. Sign in to see all of them.
Hematologic Neoplasms (5) · Melanoma (4) · Sarcoma (4) · Osteosarcoma (3) · Rhabdoid Tumor (3) · Carcinoma, Non-Small-Cell Lung (2) · Cholangiocarcinoma (2) · Chordoma (2) · Ependymoma (2) · Glioma (2) · Hepatoblastoma (2) · Histiocytosis, Langerhans-Cell (2) · Lymphoma, Non-Hodgkin (2) · Medulloblastoma (2) · Neuroblastoma (2)
Neoplasms (17) · Neoplasms by Site (15) · Neoplasms by Histologic Type (9) · Urogenital Diseases (9) · Urogenital Neoplasms (8) · Female Urogenital Diseases (7) · Female Urogenital Diseases and Pregnancy Complications (7) · Hemic and Lymphatic Diseases (7) · Neoplasms, Germ Cell and Embryonal (7) · Male Urogenital Diseases (6) · Neoplasms, Nerve Tissue (6) · Neuroectodermal Tumors (6) · Respiratory Tract Diseases (6) · Genital Diseases (5) · Hematologic Diseases (5)
Specimen Handling (12) · Biopsy (8) · Magnetic Resonance Spectroscopy (7) · X-Rays (4) · CTLA-4 Antigen (3) · Ipilimumab (3) · Nivolumab (3) · Disulfides (2) · Immunoglobulin G (2) · Phantoms, Imaging (2) · 2C4 antibody (1) · Acetaminophen (1) · CT-P13 (1) · CT-P6 (1) · Counseling (1)
National Cancer Institute (NCI) (12) · M.D. Anderson Cancer Center (8) · Academic and Community Cancer Research United (1) · City of Hope Medical Center (1)
United States (22) · Puerto Rico (3) · Australia (2) · Canada (2) · Guam (1)
A P Chen (1) · Alain C Mita (1) · Amanda Olson (1) · Amir A Jazaeri (1) · Aung Naing (1) · Betul Oran (1) · Christine A Pratilas (1) · Geoffrey I Shapiro (1) · Jordi Rodon Ahnert (1) · Malvi Savani (1) · Mary F Wedekind Malone (1) · Mellar P Davis (1) · Meredith S Irwin (1) · Patricia M LoRusso (1) · Rodabe Amaria, MD (1)
PMID 31924662, PMID 31969335, PMID 33362722, PMID 33882143, PMID 34380663, PMID 34486544, PMID 34716198, PMID 35537412, PMID 37328287, PMID 38243705, PMID 38358334, PMID 38433347, PMID 39067873, PMID 39343510, PMID 39417692, PMID 39583952, PMID 39856213, PMID 40139261, PMID 40402690, PMID 40588371, PMID 40721981, PMID 41646361, PMID 41672597, PMID 41892875, PMID 41995270, PMID 42499790, PMID 42853672
U10CA180820 (3), U10CA180886 (2), P30CA015083 (1), P30CA023074 (1), P30CA033572 (1), U01CA062490 (1), U01CA132194 (1), U10CA180821 (1), U10CA180888 (1), UG1CA242596 (1), UM1CA186688 (1), UM1CA186689 (1), UM1CA186709 (1), UM1CA186716 (1), UM1CA228823 (1)